The BSG Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This product provides a loss-of-function model for Basigin (BSG, also known as CD147 or EMMPRIN), enabling systematic investigation of its roles in tumor biology and beyond. The polyclonal format reflects a heterogeneous pool of edited cells carrying diverse mutations at the BSG locus, offering a robust platform for functional studies without selection for single-cell clones.
The HT29 parental cell line originates from a primary colorectal adenocarcinoma and displays epithelial morphology with the capacity to differentiate under appropriate conditions, mirroring aspects of human intestinal epithelium. HT29 cells are widely employed in cancer research, particularly for modeling colorectal cancer progression, epithelial differentiation, and drug transport mechanisms. Their well-characterized biology and ease of manipulation make them a dependable background for gene-editing applications.
Basigin is a transmembrane glycoprotein that orchestrates multiple signaling cascades central to tumor-stroma interactions. It is activated by upstream regulators such as TGF-??, EGFR, HIF-1??, TNF-??, and IL-6, subsequently transducing signals via the ERK1/2, p38 MAPK, and NF-??B pathways to transcriptionally upregulate matrix metalloproteinases including MMP-1, MMP-2, and MMP-9. BSG also functions as an obligate chaperone for monocarboxylate transporters MCT1 and MCT4, facilitating lactate flux, and engages in cell adhesion through interactions with integrin ??1, cyclophilin A, and caveolin-1. These activities converge to promote extracellular matrix degradation, angiogenesis via VEGF, and immune modulation, making BSG a pivotal node in invasive and metastatic programs.
In the HT29 colorectal cancer context, BSG knockout disrupts these oncogenic signaling networks, offering a physiologically relevant model to dissect the molecular underpinnings of colorectal cancer invasion and metastasis. The epithelial nature of HT29 cells coupled with BSG loss allows researchers to examine matrix metalloproteinase induction, cell?Cmatrix adhesion dynamics, and metabolic adaptations dependent on MCT-mediated lactate transport. This model is particularly suited to probing the interplay between tumor cells and the microenvironment, as BSG-driven MMP secretion influences fibroblast activation and extracellular matrix remodeling. Furthermore, given BSG??s role as a receptor for SARS-CoV-2 and in immune synapse formation, the polyclonal knockout population extends utility to infectious disease and immunology research.
Typical applications include migration and invasion assays using Boyden chambers, gelatin zymography for MMP activity, Western blotting and RT-qPCR for MMP and downstream target expression, flow cytometry for surface CD147 levels, and immunofluorescence for protein localization. Co-culture experiments with fibroblasts can recapitulate tumor?Cstroma crosstalk, while MCT-dependent lactate assays probe metabolic rewiring. Drug sensitivity testing with agents such as cisplatin or 5-fluorouracil can be performed to explore BSG-mediated chemoresistance. This polyclonal knockout cell pool provides a versatile and genetically defined tool for BSG-targeted research across oncology, inflammation, and beyond. For further details, please contact Ascent Research.
